Ilyang Pharm (007570) — Cash Flow-to-Debt Ratio
Ilyang Pharm (007570) has a Cash Flow-to-Debt Ratio of 0.01x as of June 2025, meaning its operating cash flow of ₩2.26 Billion could theoretically repay 0% of its total liabilities (₩205.41 Billion) in one year. See 007570 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ilyang Pharm Cash Flow-to-Debt Ratio (2003–2024)
Historical debt coverage capacity for Ilyang Pharm across 13 annual periods. Also explore Ilyang Pharm net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Ilyang Pharm (2003–2024)
Year-by-year debt coverage analysis for Ilyang Pharm. For market capitalisation and broader financial context, see how much is Ilyang Pharm worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | ₩5.61 Billion | ₩189.63 Billion | ▼ -64.4% |
| 2023 | 0.08x | ₩13.34 Billion | ₩160.25 Billion | ▼ -42.6% |
| 2022 | 0.15x | ₩29.94 Billion | ₩206.33 Billion | ▼ -51.8% |
| 2021 | 0.30x | ₩67.02 Billion | ₩222.51 Billion | ▲ +1.8% |
| 2020 | 0.30x | ₩57.48 Billion | ₩194.19 Billion | ▲ +75.6% |
| 2019 | 0.17x | ₩36.19 Billion | ₩214.72 Billion | ▲ +69.5% |
| 2018 | 0.10x | ₩22.12 Billion | ₩222.37 Billion | ▼ -25.3% |
| 2017 | 0.13x | ₩30.03 Billion | ₩225.39 Billion | ▲ +5.6% |
| 2016 | 0.13x | ₩26.98 Billion | ₩213.91 Billion | ▼ -30.9% |
| 2015 | 0.18x | ₩40.27 Billion | ₩220.62 Billion | ▲ +142.4% |
| 2014 | 0.08x | ₩18.63 Billion | ₩247.37 Billion | ▲ +632.0% |
| 2013 | -0.01x | ₩-3.04 Billion | ₩214.50 Billion | ▼ -112.8% |
| 2003 | 0.11x | ₩10.08 Billion | ₩91.16 Billion | — |